Drug profile · INN
evolocumab
REPATHA
evolocumab (REPATHA) is a subtilisin/kexin type 9 inhibitor. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
Drug details — evolocumab
- US status
- approved
- Class
- Cardiovascular system (C10)
- Route
- INJECTION
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
evolocumab (REPATHA) is a subtilisin/kexin type 9 inhibitor. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Subtilisin/kexin type 9 inhibitor
Primary target: Proprotein convertase subtilisin/kexin type 9
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
FDA Approves Repatha: Key Details on Amgen's Cardiovascular Drug
Repatha, recently approved by the FDA, is a groundbreaking treatment by Amgen for cardiovascular disease, targeting high cholesterol effectively.
FDA Approves Repatha for Pediatric Heterozygous Familial Hypercholesterolemia
The FDA has granted approval for Repatha, a groundbreaking treatment for pediatric patients suffering from heterozygous familial hypercholesterolemia, enhancing cholesterol control.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is evolocumab?
evolocumab (REPATHA) is a subtilisin/kexin type 9 inhibitor. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for evolocumab?
REPATHA is a marketed brand name for evolocumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of evolocumab?
evolocumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.